文献速递血栓与止血

雌激素治疗相关静脉血栓栓塞症:RIETE登记研究

Venous thromboembolism in women on estrogen therapy: presentation, management, and outcomes in the RIETE registry.
PubMed 文献 · Blood Adv · 2026-01-01

基于RIETE登记2011-2024年数据,分析50岁以下无癌症的急性VTE患者,其中2786例女性在雌激素治疗期间发生VTE。雌激素相关VTE女性更年轻,92%诊断时停用雌激素,抗凝中出血率高于男性,但停抗凝后复发率最低。

要点

  • 雌激素相关VTE女性更年轻,74%无其他短暂危险因素。
  • 诊断时92%停用雌激素,中位抗凝6个月。
  • 抗凝期间出血率女性高于男性,停抗凝后复发率最低。

核心结论

  • 雌激素治疗相关VTE女性较年轻,抗凝期间出血率高于男性,但停抗凝后复发风险低。

主要发现

  • 雌激素相关VTE女性平均年龄32±9岁,低于男性39±8岁和其他女性38±8岁(P< .001)。
  • 74%的雌激素相关VTE病例无其他短暂危险因素。
  • 抗凝期间出血率:雌激素相关VTE女性8.70/100患者年(95%CI 7.09-10.6),非雌激素相关VTE女性11.8(95%CI 10.0-13.7),均高于男性5.46(95%CI 4.64-6.39;P< .05)。
  • 停抗凝后复发率:雌激素相关VTE女性2.07/100患者年(95%CI 1.57-2.68),低于男性8.70(95%CI 7.75-9.73;P< .001)和其他女性5.05(95%CI 4.16-6.07;P< .001)。

关键数值与推荐

  • 诊断时92%的雌激素相关VTE病例停用雌激素治疗。
  • 中位抗凝持续时间为6个月(四分位距4-9)。

临床怎么用

  • 对雌激素治疗期间发生VTE的年轻女性,应停用雌激素并给予抗凝治疗,注意监测出血风险。
  • 停抗凝后复发风险较低,可考虑较短疗程抗凝。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Combined oral contraceptives increase the venous thromboembolism (VTE) risk nearly fivefold. Their widespread use translates into a substantial number of VTE events in otherwise healthy young women. However, data on estrogen-associated VTE remain limited. We used data from the RIETE registry (2011-2024), including patients without cancer <50 years with acute VTE. We analyzed the presentation, management, and outcomes in women with estrogen-associated VTE and compared them with men and women with non-estrogen-associated VTE. Among 13 418 patients, 2786 women experienced a VTE during estrogen therapy. They were younger (mean age ± standard deviation, 32 ± 9 years) than men (39 ± 8; P< .001) and other women (38 ± 8; P< .001). In 74% of estrogen-associated VTE cases, no additional transient risk factors were present. Estrogen therapy was discontinued in 92% of cases at diagnosis. The median anticoagulation duration was 6 months (interquartile range, 4-9). Bleeding during anticoagulation was more frequent in women with estrogen-associated VTE (8.70 per 100 patient-years; 95% confidence interval [CI], 7.09-10.6) and women with non-estrogen-associated VTE (11.8; 95% CI, 10.0-13.7) than in men (5.46; 95% CI, 4.64-6.39; P< .05). After stopping anticoagulation, recurrence was lowest in women with estrogen-associated VTE (2.07 per 100 patient-years; 95% CI, 1.57-2.68) compared with men (8.70; 95% CI, 7.75-9.73; P< .001) and other women (5.05; 95% CI, 4.16-6.07; P< .001). Women with VTE during estrogen therapy were younger. Bleeding during anticoagulation was more frequent among women than among men. Women with estrogen therapy-associated VTE had a low recurrence risk in the first year after stopping anticoagulation.

来源:Blood Adv,查看原文。版权归原作者所有。

引用

  1. Verstraete A, Vanassche T, Blanco-Molina A, et al. Venous thromboembolism in women on estrogen therapy: presentation, management, and outcomes in the RIETE registry. Blood Adv. 2026. PMID: 42379249. doi:10.1182/bloodadvances.2026020383

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。